Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

BACKGROUND: Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation. OBJECTIVE: This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019. METHODS: We conducted a prospective, mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yang, Wei, Jia, Zou, Liang, Jiang, Tiebin, Wang, Gaoxiang, Chen, Liting, Huang, Liang, Meng, Fankai, Huang, Lifang, Wang, Na, Zhou, Xiaoxi, Luo, Hui, Mao, Zekai, Chen, Xing, Xie, Jungang, Liu, Jing, Cheng, Hui, Zhao, Jianping, Huang, Gang, Wang, Wei, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2020
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250105/
https://www.ncbi.nlm.nih.gov/pubmed/32470486
http://dx.doi.org/10.1016/j.jaci.2020.05.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250105/
https://www.ncbi.nlm.nih.gov/pubmed/32470486
http://dx.doi.org/10.1016/j.jaci.2020.05.019

Ejemplares similares